$FEMY
FEMASYS INC

2024 Q3 Form 10-Q Financial Statement

#000114036124036299 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $554.9K $221.5K $320.5K
YoY Change 127.09% -30.9% 5.74%
Cost Of Revenue $190.8K $73.13K $110.5K
YoY Change 121.43% -33.8% 7.93%
Gross Profit $364.1K $148.4K $210.0K
YoY Change 130.17% -29.37% 4.62%
Gross Profit Margin 65.61% 66.98% 65.53%
Selling, General & Admin $3.103M $2.587M $1.486M
YoY Change 52.01% 74.15% 19.31%
% of Gross Profit 852.31% 1743.75% 707.25%
Research & Development $2.303M $1.976M $1.527M
YoY Change 11.12% 29.38% 3.68%
% of Gross Profit 632.64% 1331.82% 727.07%
Depreciation & Amortization $76.28K $67.63K $133.3K
YoY Change -42.08% -49.27% -6.57%
% of Gross Profit 20.95% 45.59% 63.47%
Operating Expenses $5.483M $4.631M $3.146M
YoY Change 29.32% 47.19% 9.97%
Operating Profit -$5.118M -$4.482M -$2.936M
YoY Change 25.41% 52.66% 10.38%
Interest Expense -$289.3K -$204.2K $198.00
YoY Change -3700.9% -103216.16% -77.58%
% of Operating Profit
Other Income/Expense, Net -$289.3K -$204.2K $42.45K
YoY Change -442.89% -580.93% 64.16%
Pretax Income -$5.408M -$4.686M -$2.894M
YoY Change 35.3% 61.96% 9.85%
Income Tax $1.158K -$1.750K $0.00
% Of Pretax Income
Net Earnings -$5.409M -$4.685M -$2.894M
YoY Change 35.33% 61.9% 9.85%
Net Earnings / Revenue -974.73% -2115.08% -902.77%
Basic Earnings Per Share -$0.24 -$0.21 -$0.22
Diluted Earnings Per Share -$0.24 -$0.21 -$0.22
COMMON SHARES
Basic Shares Outstanding 22.23M 22.22M 13.19M
Diluted Shares Outstanding 22.23M 22.22M 13.11M

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.611M $13.53M $10.71M
YoY Change -12.44% 26.35% -44.0%
Cash & Equivalents $7.611M $13.53M $10.71M
Short-Term Investments
Other Short-Term Assets $1.371M $997.6K $587.8K
YoY Change 65.85% 69.71% -31.25%
Inventory $1.938M $1.316M $581.5K
Prepaid Expenses
Receivables $378.3K $92.54K $155.7K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $11.30M $15.93M $12.03M
YoY Change 10.49% 32.43% -40.82%
LONG-TERM ASSETS
Property, Plant & Equipment $1.388M $1.262M $1.255M
YoY Change 19.62% 0.56% -23.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $887.4K $957.1K $865.6K
YoY Change -5.29% 10.57% 30.54%
Total Long-Term Assets $4.287M $4.345M $2.284M
YoY Change -7.37% 90.24% -18.18%
TOTAL ASSETS
Total Short-Term Assets $11.30M $15.93M $12.03M
Total Long-Term Assets $4.287M $4.345M $2.284M
Total Assets $15.59M $20.28M $14.31M
YoY Change 4.93% 41.66% -38.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.122M $951.5K $546.9K
YoY Change 31.69% 73.99% 27.68%
Accrued Expenses $1.128M $886.4K $536.8K
YoY Change 98.03% 65.11% -2.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $209.1K
YoY Change -74.26%
Total Short-Term Liabilities $2.867M $2.464M $1.382M
YoY Change 31.12% 78.35% -25.91%
LONG-TERM LIABILITIES
Long-Term Debt $5.069M $4.758M $0.00
YoY Change 133.69% -100.0%
Other Long-Term Liabilities $1.679M $1.804M $56.25K
YoY Change 3008.66% 3107.45% -48.46%
Total Long-Term Liabilities $6.748M $6.562M $56.25K
YoY Change 203.55% 11567.19% -82.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.867M $2.464M $1.382M
Total Long-Term Liabilities $6.748M $6.562M $56.25K
Total Liabilities $9.615M $9.026M $1.438M
YoY Change 118.04% 527.78% -34.14%
SHAREHOLDERS EQUITY
Retained Earnings -$122.1M -$116.7M -$99.97M
YoY Change 17.41% 16.7% 13.28%
Common Stock $22.35K $22.35K $15.19K
YoY Change 38.73% 47.14% 27.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.970M $11.25M $12.88M
YoY Change
Total Liabilities & Shareholders Equity $15.59M $20.28M $14.31M
YoY Change 4.93% 41.66% -38.09%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$5.409M -$4.685M -$2.894M
YoY Change 35.33% 61.9% 9.85%
Depreciation, Depletion And Amortization $76.28K $67.63K $133.3K
YoY Change -42.08% -49.27% -6.57%
Cash From Operating Activities -$5.475M -$4.327M -$2.741M
YoY Change 91.79% 57.84% 15.18%
INVESTING ACTIVITIES
Capital Expenditures $440.0K $207.0K $62.95K
YoY Change 1416.3% 228.77% -136.04%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$440.0K -$207.0K -$62.95K
YoY Change 1416.3% 228.77% -63.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 223.5K 3.348M
YoY Change -100.0% -93.32% -3563.85%
NET CHANGE
Cash From Operating Activities -5.475M -4.327M -2.741M
Cash From Investing Activities -440.0K -207.0K -62.95K
Cash From Financing Activities 0.000 223.5K 3.348M
Net Change In Cash -5.915M -4.310M 543.7K
YoY Change 194.33% -892.76% -120.51%
FREE CASH FLOW
Cash From Operating Activities -$5.475M -$4.327M -$2.741M
Capital Expenditures $440.0K $207.0K $62.95K
Free Cash Flow -$5.915M -$4.534M -$2.804M
YoY Change 105.12% 61.68% 27.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001339005
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q2 femy Stock Issued During Period Value Issuance Of Common Stock And Warrants
StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrants
3345996
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1697
CY2023Q2 femy Stock Issued During Period Value Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
188
femy Number Of Products Received Eumdr And Ce Mark Certifications
NumberOfProductsReceivedEUMDRAndCEMarkCertifications
4
CY2024Q2 femy Number Of Women Used Fem Bloc For Permanent Birth Control
NumberOfWomenUsedFemBlocForPermanentBirthControl
401
femy Number Of Year Where Women S Used For Permanent Birth Control
NumberOfYearWhereWomenSUsedForPermanentBirthControl
P1Y
femy Number Of Women Need To Use For Interim Analysis Of Clinical Data
NumberOfWomenNeedToUseForInterimAnalysisOfClinicalData
300
CY2024Q2 femy Accrued Clinical Trial Cost
AccruedClinicalTrialCost
334799
CY2023Q4 femy Accrued Clinical Trial Cost
AccruedClinicalTrialCost
276141
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
250025
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0
CY2024Q2 femy Incentive And Other Compensation Costs Current
IncentiveAndOtherCompensationCostsCurrent
170328
CY2023Q4 femy Incentive And Other Compensation Costs Current
IncentiveAndOtherCompensationCostsCurrent
1082606
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
70000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
60210
CY2024Q2 femy Franchise Taxes
FranchiseTaxes
3150
CY2023Q4 femy Franchise Taxes
FranchiseTaxes
12160
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
58050
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13179
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
886352
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1444296
CY2023Q4 femy Clinical Holdback Liability
ClinicalHoldbackLiability
120235
femy Clinical Holdback Retained
ClinicalHoldbackRetained
5990
femy Clinical Holdback Paid
ClinicalHoldbackPaid
1122
CY2024Q2 femy Clinical Holdback Liability
ClinicalHoldbackLiability
125103
CY2024Q2 femy Clinical Holdback Current
ClinicalHoldbackCurrent
92397
CY2024Q2 femy Clinical Holdback Noncurrent
ClinicalHoldbackNoncurrent
32706
CY2024Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2023Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
femy Percentage Of Restocking Fee
PercentageOfRestockingFee
0.30
CY2023Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3899813
CY2023Q2 femy Placement Agent Fees Expenses And Offering Expenses
PlacementAgentFeesExpensesAndOfferingExpenses
547764
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22232799
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
104013
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
65216
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
181598
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
122170
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1516737
femy Share Based Compensation Expense To Be Recognized Upon Achieving Certain Performance Condition
ShareBasedCompensationExpenseToBeRecognizedUponAchievingCertainPerformanceCondition
155222
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1361515
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M18D
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1318000
CY2023Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3899813
CY2023Q2 femy Payments Of Equity Issuance Costs
PaymentsOfEquityIssuanceCosts
547764
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1133480
CY2023Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
3352049
CY2023Q4 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
5000000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4684574
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4684574
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2893508
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2893508
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8284084
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8284084
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5839765
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5839765
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22215516
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22215516
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13107590
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13107590
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21995436
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21995436
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12493334
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12493334
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2024Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3171139
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1169671
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3171139
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1169671
CY2024Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
196816
CY2023Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
233460
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
196816
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
233460
CY2024Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
15046930
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4791656
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
15046930
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4791656
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001140361-24-036299-index-headers.html Edgar Link pending
0001140361-24-036299-index.html Edgar Link pending
0001140361-24-036299.txt Edgar Link pending
0001140361-24-036299-xbrl.zip Edgar Link pending
ef20029680_10q.htm Edgar Link pending
ef20029680_ex31-1.htm Edgar Link pending
ef20029680_ex31-2.htm Edgar Link pending
ef20029680_ex32-1.htm Edgar Link pending
ef20029680_ex32-2.htm Edgar Link pending
femy-20240630.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
femy-20240630_lab.xml Edgar Link unprocessable
femy-20240630_pre.xml Edgar Link unprocessable
ef20029680_10q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
femy-20240630_cal.xml Edgar Link unprocessable
femy-20240630_def.xml Edgar Link unprocessable